Table 2.
Summary of differentially expressed lncRNAs in parathyroid tumors.
| Candidate lncRNAs |
Expression Levels | lncRNA Expression Profiling Platform |
AUC Value | Study |
|---|---|---|---|---|
| LINC00959, lnc-FLT3-2:2, lnc-FEZF2-9:2, and lnc-RP11-1035H13.3.1-2:1 |
↓ and ↑ | Microarray, qPCR |
0.88 (global lncRNA score) for discriminating PCs from adenoma | [43] |
| ROR | In situ hybridization assay, qPCR | / | [44] | |
| BC200, HAR1B, HOXA3as, NEAT1, SNHG6, and ZFAS1 |
↑ | In situ hybridization assay, qPCR | 0.74 (BC200) for discriminating PCs from adenoma and atypical adenomas, and for discriminating PCs with CDC73 mutation from wild-type carcinomas | [45] |
| PVT1 and GLIS2-AS1 | ↑ and ↓ | Microarray, qPCR |
0.871 (PVT1), 0.860 (GLIS2-AS1), for discriminating between PC patients and adenoma patients 0.950 (PVT1), 0.933 (GLIS2-AS1), for discriminating PCs with CDC73 mutation from wild-type carcinomas |
[46] |
↑, increase in lncRNA expression levels; ↓, reduction in lncRNA expression levels.